Perneczky Biomarkers for Alzheimer’s Disease Drug Development

2. Auflage 2024
ISBN: 978-1-0716-3774-6
Verlag: Springer US
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 2785, 347 Seiten, eBook

Reihe: Methods in Molecular Biology

This fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic.  Authoritative and practical, Biomarkers for Alzheimer’s Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Perneczky, Robert

Inhaltsverzeichnis

Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis in Real-World Settings.- Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approaches.- CSF N-Glycomics Using High Throughput UPLC-ESI Techniques in Alzheimer’s Disease.- CSF N-Glycomics Using MALDI MS Techniques.- Optimized Pre-Analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Disease.- Mass Spectrometry-Based Metabolomics Multi-Platform for Alzheimer’s Disease Research.- Analysis of Resting-State Functional Magnetic Resonance Imaging in Alzheimer's Disease.- Diffusion Tensor Imaging in Alzheimer’s Studies.- Magnetic Resonance Spectroscopy (MRS) in Alzheimer’s Disease.- Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies.- Amyloid PET Imaging: Standard Procedures and Semiquantification.- PET Imaging to Measure Neuroinflammation In Vivo.- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.- High-Throughput Lipidomics and Metabolomics Profiling for Brain Tissue and Biofluid Samples in Neurodegenerative Disorders.- Neuropathological Assessment as an Endpoint in Clinical Trial Design.- Non-Invasive Visualization of Amyloid-Beta Deposits in Alzheimer’s Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent.- Brain Banking in Dementia Studies.- Speech-Based Digital Biomarkers for Alzheimer’s Research.- cCOG Web-Based Cognitive Assessment Tool.- In Silico Models to Validate Novel Blood-Based Biomarkers.